Cancer Immunology, Immunotherapy

, Volume 62, Issue 6, pp 1123–1130

Elevated level of peripheral CD8+CD28 T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy

  • Guohong Song
  • Xiaoli Wang
  • Jun Jia
  • Yanhua Yuan
  • Fengling Wan
  • Xinna Zhou
  • Huabing Yang
  • Jun Ren
  • Jiezhun Gu
  • Herbert Kim Lyerly
Original Article

DOI: 10.1007/s00262-013-1424-8

Cite this article as:
Song, G., Wang, X., Jia, J. et al. Cancer Immunol Immunother (2013) 62: 1123. doi:10.1007/s00262-013-1424-8

Abstract

Purpose

Suppression of cellular immunity resulting from tumorigenesis and/or therapy might promote cancer cells’ growth, progression and invasion. Here, we explored whether T lymphocyte subtypes from peripheral blood of metastatic breast cancer (MBC) female patients could be used as alternative surrogate markers for cancer progress. Additionally, plasma levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IFN-γ, and transforming growth factor-β1 were quantitated from MBC and healthy volunteers.

Experimental design

This study included 89 female MBC patients during the post-salvage chemotherapy follow-up and 50 age- and sex-matched healthy volunteers as control. The percentages of T lymphocyte subpopulations from peripheral blood and plasma levels of cytokines were measured.

Results

Both CD8+CD28 and CD4+CD25+ were elevated in MBC patients compared to the control cohort (P < 0.05). In contrast, CD3+ and CD8+CD28+cells were significantly lower in MBC patients (P < 0.0001, P = 0.045, respectively). MBC patients had elevated levels of immunosuppressive cytokines IL-6 and IL-10. Patients with elevated CD8+CD28 and CD4+CD25+ cells showed increased levels of IL-6, and only patients with elevated CD8+CD28 had decreased interferon-γ. Univariate analysis indicated increased CD3+CD4+ or CD8+CD28+correlated with prolonged progression-free survival (PFS), while elevated CD8+CD28associated with shorten PFS. The percent of CD8+CD28 T lymphocytes is an independent predictor for PFS through multivariate analysis.

Conclusions

This study suggests that progressive elevated levels of CD8+CD28 suppressor T lymphocytes represent a novel independent predictor of PFS during post-chemotherapy follow-up.

Keywords

Regulatory T lymphocytePeripheral bloodMetastatic breast cancerProgression-free survivalCytokine

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Guohong Song
    • 1
  • Xiaoli Wang
    • 1
    • 2
  • Jun Jia
    • 1
  • Yanhua Yuan
    • 1
  • Fengling Wan
    • 1
  • Xinna Zhou
    • 1
    • 2
  • Huabing Yang
    • 1
    • 2
  • Jun Ren
    • 1
    • 2
  • Jiezhun Gu
    • 4
  • Herbert Kim Lyerly
    • 3
  1. 1.Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)Peking University Cancer Hospital and InstituteBeijingChina
  2. 2.Capital Medical University Cancer CenterBeijing Shijitan HospitalBeijingChina
  3. 3.Department of SurgeryDuke University Medical CenterDurhamUSA
  4. 4.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA